UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

 

Date of report (Date of earliest event reported): June 27, 2018

 

AYTU BIOSCIENCE, INC.

 

(Exact Name of Registrant as Specified in Charter)

 

Delaware   001-38247   47-0883144
(State or Other Jurisdiction
of Incorporation)
  (Commission File Number)   (IRS Employer
Identification No.)

 

373 Inverness Parkway, Suite 206, Englewood, Colorado   80112
(Address of Principal Executive Offices)   (Zip Code)

 

Registrant’s Telephone Number, Including Area Code: (720) 437-6580

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions ( see General Instruction A.2. below):

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

 

Item 5.07 Submission of Matters to a Vote of Security Holders.

 

The 2018 annual meeting of stockholders for Aytu BioScience, Inc. for the fiscal year ended June 30, 2018 was held on June 27, 2018. Of the 35,883,069 shares outstanding on the record date for the meeting, a total of 27,180,123 shares were present or represented at the meeting.

 

At the meeting, our stockholders elected five members to our board of directors as follows:

 

Members   Number of Votes Cast For   Number of Votes Cast Against   Number of Votes Withheld   Number of Broker Non-Votes
                 
Joshua R. Disbrow   10,015,887   0   1,562,549   15,601,687
                 
Gary V. Cantrell   9,931,570   0   1,646,866   15,601,687
                 
Carl C. Dockery   9,937,116   0   1,641,320   15,601,687
                 
John A. Donofrio, Jr.   10,238,033   0   1,340,403   15,601,687
                 
Michael E. Macaluso   9,967,263   0   1,611,173   15,601,687

 

The election of directors was determined by a plurality of the votes cast at the meeting, whereby the five nominees receiving the highest number of “FOR” votes were elected as directors.

 

At the meeting, our stockholders took the following actions:

 

Did not approve an amendment to our certificate of incorporation to increase the number of authorized shares of common stock from 100,000,000 to 300,000,000 shares of common stock. The vote was 16,288,316 shares for, 10,321,933 shares against, 569,874 shares abstaining, and no shares of broker non-votes;

 

Approved, by a majority of the shares of our outstanding capital stock, an amendment to our certificate of incorporation to effect a reverse stock split at a ratio of any whole number up to 1-for-20, as determined by the board of directors, at any time before our next annual meeting. The vote for such approval was 18,053,733 shares for, 8,948,996 shares against, 177,394 shares abstaining, and no shares of broker non-votes; and

 

Ratified, by a majority of the shares voting at the meeting, the appointment of EKS&H, LLLP as our independent registered public accounting firm for the fiscal year ending June 30, 2018. The vote for such approval was 22,207,381 shares for, 2,657,778 shares against, 2,314,964 shares abstaining, and no shares of broker non-votes.

 

1

 

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  AYTU BIOSCIENCE, INC.
   
Date: July 2, 2018 By:  /s/ David Green
    Name: David Green
Title: Chief Financial Officer

 

 

2

 

 

AYTU BioPharma (NASDAQ:AYTU)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more AYTU BioPharma Charts.
AYTU BioPharma (NASDAQ:AYTU)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more AYTU BioPharma Charts.